Features

Viewpoints

All the Guidelines in the World Can’t Eliminate Gray Areas

By

Jim Anderson, MPAS, PA-C, DFAAPA

Publish Date May 31, 2022

Jim Anderson, MPAS, PA-C, explores the role and limits of guidelines.

Adagrasib Shows Promising Activity in Gastrointestinal Cancers

By

Alan P. Lyss, MD

Publish Date February 4, 2022

In the KRYSTAL-1 trial, adagrasib produced a 100% disease control rate in patients with gastrointestinal cancers.

From the Advisory Board

We Can Treat Hodgkin’s Lymphoma Like Melanoma?

By

Isabel Cunningham, MD

Publish Date September 3, 2015

Isabel Cunningham, MD, Cancer Therapy Advisor Advisory Board member, weighs in on recent discoveries in the treatment of hematologic cancers.

Slideshows

BAVENCIO (avelumab) for Merkel Cell Carcinoma

IMLYGIC (talimogene laherparepvec) for Melanoma

Features

Medicine vs Food: The Patient Care Dilemma of Financial Toxicity

By

Jody A. Charnow

Publish Date November 23, 2022

Physicians are calling on colleagues to bring up the cost of care and its potential impact when discussing treatment options with patients.

Up to 10% of Early-Onset mCRC Cases May Be Driven by Undiagnosed IBD

By

Alan P. Lyss, MD

Publish Date November 15, 2022

As many as 10% of early-onset metastatic colorectal cancer cases may be attributable to undiagnosed inflammatory bowel disease, a study suggests.

Duration of ET Tied to Benefit in DCIS, but Young Patients May Reject ET

By

Alan P. Lyss, MD

Publish Date November 11, 2022

Two new studies shed light on the complexity of preventing subsequent breast cancer events in patients with ductal carcinoma in situ.